Lau J Y, Davis G L, Brunson M E, Qian K P, Lin H J, Quan S, DiNello R, Polito A J, Scornik J C
Department of Medicine, University of Florida, Gainesville 32610.
Hepatology. 1993 Nov;18(5):1027-31. doi: 10.1016/0270-9139(93)90452-s.
To determine the prevalence and significance of hepatitis C virus infection in kidney transplant recipients, paired serum samples collected from 100 renal allograft recipients on admission for kidney transplantation and 1 yr after transplantation were tested for antibody to hepatitis C virus with second-generation enzyme immunoassay and recombinant immunoblot assay and for hepatitis C virus RNA with reverse transcription-polymerase chain reaction. Before kidney transplantation, hepatitis C virus antibody was detected with second-generation enzyme immunoassay in 18 patients (12 second-generation recombinant immunoblot assay-positive, 6 second-generation recombinant immunoblot assay-indeterminate). Nine of 12 second-generation recombinant immunoblot assay-positive and 2 of 6 second-generation recombinant immunoblot assay-indeterminate samples were hepatitis C virus RNA positive. In addition, 7 of 82 patients who had no detectable antibody on second-generation enzyme immunoassay or second-generation recombinant immunoblot assay were hepatitis C virus RNA positive. After kidney transplantation, hepatitis C virus antibody was detected in 19 patients (12 second-generation recombinant immunoblot assay-positive, 7 second-generation recombinant immunoblot assay-indeterminate, 14 seropositive for hepatitis C virus antibody). Eleven of 12 patients with second-generation recombinant immunoblot assay-positive results and 4 of 7 with second-generation recombinant immunoblot assay-indeterminate results were positive for hepatitis C virus RNA. Hepatitis C virus RNA was present in 28 patients 1 yr after kidney transplantation. Six patients appeared to have acquired active hepatitis C virus infection 1 yr after kidney transplantation (seroconverted to hepatitis C virus RNA positivity).(ABSTRACT TRUNCATED AT 250 WORDS)
为确定肾移植受者中丙型肝炎病毒感染的患病率及意义，对100例肾移植受者在肾移植入院时及移植后1年采集的配对血清样本，采用第二代酶免疫测定法和重组免疫印迹法检测丙型肝炎病毒抗体，并用逆转录 - 聚合酶链反应检测丙型肝炎病毒RNA。肾移植前，第二代酶免疫测定法检测出18例患者丙型肝炎病毒抗体阳性（12例第二代重组免疫印迹法阳性，6例第二代重组免疫印迹法结果不确定）。12例第二代重组免疫印迹法阳性样本中的9例及6例第二代重组免疫印迹法结果不确定样本中的2例丙型肝炎病毒RNA阳性。此外，82例第二代酶免疫测定法或第二代重组免疫印迹法未检测到抗体的患者中有7例丙型肝炎病毒RNA阳性。肾移植后，19例患者检测到丙型肝炎病毒抗体（12例第二代重组免疫印迹法阳性，7例第二代重组免疫印迹法结果不确定，14例丙型肝炎病毒抗体血清学阳性）。12例第二代重组免疫印迹法阳性结果患者中的11例及7例第二代重组免疫印迹法结果不确定患者中的4例丙型肝炎病毒RNA阳性。肾移植后1年，28例患者存在丙型肝炎病毒RNA。6例患者在肾移植后1年似乎获得了活动性丙型肝炎病毒感染（血清转化为丙型肝炎病毒RNA阳性）。（摘要截短于250字）
